Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Bone Repair Cells: Final Phase I/II data

Final data from a open-label, U.S. Phase I/II trial in 36 patients

Read the full 128 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE